PTC THERAPEUTICS INC (PTCT)
Health Care · Specialty Biopharmaceuticals / Gene Therapy · NASDAQ
PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved products and partnered collaboration deals.
What PTC THERAPEUTICS INC does
PTC Therapeutics is a biopharmaceutical company that discovers, develops, and commercializes drugs and gene therapy products for serious genetic disorders, neurological conditions, and oncology. The company generates revenue from net product sales, royalties, and collaboration/licensing arrangements with partners. With a current market cap of ~$7.3B and positive net margin, PTC maintains a portfolio of approved products and clinical-stage candidates across multiple therapeutic areas.
Themes: ["Gene therapy","Rare genetic disorders","Neurological diseases","Precision medicine","Biopharmaceuticals"]
Fundamentals
- Price$89.55 as of 2026-07-09 close
- Market cap$7.3B as of 2026-07-10
- 1-year return+83.7% as of 2026-07-09 close
- P/E994.56 as of 2026-07-10
- Net margin+0.9% as of 2026-07-10
- Gross margin+32.6% as of 2026-07-10
- ROE+0.1% as of 2026-07-10
- Debt / equity0.03 as of 2026-07-10
- Revenue growth (YoY)-53.3% as of 2026-07-10
- Revenue CAGR (3y)+35.3% SEC XBRL
- Beta0.53 as of 2026-07-10
Key risks (from latest filing)
["Regulatory approval risk: FDA review and approval processes for gene therapies and new drug candidates are complex and uncertain; clinical holds can be imposed at any time during trials due to safety concerns","Revenue concentration risk: Q1 2026 collaboration/license revenue collapsed 86% YoY (from $986M to $143K), indicating heavy dependence on partnership deals that may not recur","Debt and royalty obligations: Company carries ~$2.3B in liabilities for sale of future royalties (current + noncurrent), creating fixed obligations against product revenue that declined 53% YoY"]
Competitors & peers
- Biogen (BIIB)
- Audentes Therapeutics (acquired by Astellas)
- Sarepta Therapeutics (SRPT)
- Sangamo Therapeutics (SGMO)
- Regenxbio (RGNX)
- Spark Therapeutics (acquired by Roche)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.